700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
The objectives of this study were to prepare and characterize the novel Lomefloxacin-Salicylic acid and Lomefloxacin-Urea to demonstrate the enhanced dissolution of Lomefloxacin by co crystal formation in comparison with the pure drug. Lomefloxacin-Salicylic acid and Lomefloxacin-Urea co crystal was prepared using greener technique cogriding with aim of enhancing their dissolution rate sand their bioavailability. DSC, IR and PXRD were used to characterize the novel solid form. The dissolution and chemical stability were assessed and compared with marketed Maxaquin. Pharmaceutical co crystals are new solid forms with physicochemical properties that appear promising for drug product development. Novel solid co crystals with distinct melting. DSC, FTIR and PXRD data was obtained. The co crystal of lomefloxacin with salicylic acid (SA) has been shown to have higher solubility than lomefloxacin. In this study, we aimed to characterize the pure drug and the co crystals with the salicylic acid and urea. Remarkably, two new co crystals of lomefloxacin were discovered in this study. The study indicates that the improved aqueous solubility of the co crystals leads to improved dissolution of Lomefloxacin. Thus, the co crystals are a viable alternative solid form that can improve the dissolution rate and bioavailability of poorly soluble drugs. Subsequently, differential scanning calorimetry was used to investigate the co crystal formation. The formation of co crystals was also verified using liquid-assisted grinding. The spectral patterns of lomefloxacin, salicylic acid and the complex were different. The physicochemical properties such as solubility and dissolution rate of this complex will be further investigated.
Lomefloxacin, dissolution rates, cocrystals, product development